Healios K.K.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 6 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/13 | ¥-11.14 | ¥-27.65 | -148.2% |
| 2026/02/15 | ¥8.63 | ¥18.90 | +119.1% |
| 2025/11/12 | ¥6.37 | ¥7.54 | +18.4% |
| 2025/08/12 | ¥-6.79 | ¥-20.31 | -199.1% |
Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
American Century ETF Trust-Avantis International Small Cap Equity ETF
|
200 | -95.45% |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥90M | ¥121M | ¥560M | ¥104M |
| Gross Profit | ¥90M | ¥109M | ¥432M | -¥114M |
| Operating Income | -¥5,179M | -¥3,379M | -¥2,842M | -¥3,340M |
| Pretax Income | -¥4,830M | -¥2,922M | -¥2,472M | -¥1,926M |
| Net Income | -¥5,169M | -¥3,823M | -¥4,235M | -¥2,217M |
| EPS | -¥90.67 | -¥56.22 | -¥47.86 | -¥26.60 |
| Operating Margin | -5,754.44% | -2,792.56% | -507.50% | -3,211.54% |
| Balance Sheet | ||||
| Total Assets | ¥15,033M | ¥15,155M | ¥14,191M | ¥17,054M |
| Total Equity | ¥4,382M | ¥3,856M | ¥2,063M | ¥4,890M |
| Total Liabilities | ¥10,651M | ¥11,299M | ¥12,128M | ¥12,164M |
| Cash | ¥7,247M | ¥6,722M | ¥3,672M | ¥5,679M |
| Interest-bearing Debt | ¥7,146M | ¥4,532M | ¥2,663M | ¥2,612M |
| Equity Ratio | 29.15% | 25.44% | 14.54% | 28.67% |
| D/E Ratio | 1.63 | 1.18 | 1.29 | 0.53 |
| Cash Flow | ||||
| Operating CF | -¥4,601M | -¥2,822M | -¥1,817M | -¥3,165M |
| Investing CF | -¥909M | -¥1,121M | -¥1,418M | -¥1,114M |
| Financing CF | -¥2,502M | ¥3,337M | ¥77M | ¥6,335M |
| Free CF | -¥4,863M | -¥2,850M | -¥2,124M | -¥3,333M |
| Efficiency | ||||
| ROE | -117.96% | -99.14% | -205.28% | -45.34% |
| ROA | -34.38% | -25.23% | -29.84% | -13.00% |
Latest IR Information
-
IFRS Consolidated Financial Results for the 2026 Fiscal Year Ending December 2026 - Second Quarter (Interim) Financial Summary
Consolidated results for the six months ended December 2026 show net sales of 15 million yen, operating loss of 2,404 million yen, and net loss attributable to owners of the parent of 2,286 million yen. Compared with the same period...
Read more -
Fiscal Year 2026 Ending December, Second Quarter Financial Results Briefing
This document is the financial results briefing for the second quarter of the fiscal year ending December 2026. It is highly likely to disclose sales, income figures, segment performance, and future outlook.
Read more -
Notice on the Accounting of Financial income and Financial expenses
For the cumulative second quarter of the 2026 fiscal year, financial income was 1,111 million yen and financial expenses were 985 million yen, with notable components including fair value gains on securities of 1,079 million yen, interest income of 30...
Read more -
N/A
Our company has been adopted as a support research project under AMED for industrializing regenerative medicine and gene therapy, and is advancing the development of a commercial production process for eNK® cells for the treatment of intractable cancers. The direct...
Read more -
Announcement on the finalization of the issuance content for Issued Stock Options (29th Stock Acquisition Rights)
Issuance contents for stock options have been finalized. Recipients: 52 people; total issued: 121,356 units; shares subject to exercise: common shares 12,135,600.
Read more -
Notice Regarding Finalization of Issuance Details for Stock Options (30th Series)
Issuance of 54,610 stock options to CEO Tadanao KagiMoto, total of 54,610 options, with 5,461,000 ordinary shares underlying.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥780
Rating Score: 1.50 (Based on 6 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration and AKT-01/HLCN061, which is in pre-clinical trial for the treatment of Mesothelioma, Lung cancer, Hepatocellular carcinoma and Gastric cancer(solid tumors). It also develops somatic stem cell and induced pluripotent stem cell regenerative medicines. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Chiyoda, Japan.
